Perl A, Martinelli G, Cortes J, et al. Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3MUT+) relapsed/refractory (R/R) acute myeloid leukemia (AML): results from the phase 3 ADMIRAL trial. 24th Congress of EHA, abstract A876.
Involved-fieldradiotherapie voorkomt recidief bij vroeg stadium PET-negatief HL na ABVD
dec 2021 | Lymfoom, Radiotherapie